Head-to-head · WeighScore
FuturHealth vs Roboclinic
The verdict
FuturHealth takes it — 65.6/100 to 65.3/100, but only just.
FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added Roboclinic is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | Roboclinic |
|---|---|---|
| WeighScore | 65.6/100 | 65.3/100 |
| Grade | C | C |
| Scorecard rank | #215 | #223 |
| Semaglutide | $199/mo (compounded) | $179/mo (12-month plan, compounded) |
| Tirzepatide | Not disclosed | $299/mo (12-month plan, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #223 · C
Strengths
- Compounded semaglutide from $179/mo and tirzepatide from $299/mo on 12-month plans
- One all-in price bundles the provider consult, prescription, and delivery
- Offers both injectable and oral (tablet) compounded semaglutide
- 'Same price, every dose' means your cost does not rise as the dose increases
- AI-first intake with board-certified provider review; no insurance necessary
Where it loses points
- Lowest rates require a 12-month plan; month-to-month runs $299/mo (semaglutide) to $399/mo (tirzepatide)
- Individual compounding pharmacies are not named; fulfillment is routed through OpenLoop Health
- No published per-state list; site claims 'all 50 states, restrictions apply' and gates doctor review by region
- Refunds limited to your most recent billing cycle; none for used or partially used periods
- Operated by BrickFi, Inc., a newer brand with limited independent track record
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.